Victoria Patterson

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva et al. · The Lancet Oncology · 2021 · 102 citations

Medicine, Hematology, Pharmacology +11

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

Matthew S. Davids, Christine E. Ryan, Benjamin L. Lampson et al. · Journal of Clinical Oncology · 2024 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Benjamin L. Lampson, Svitlana Tyekucheva, Jennifer L. Crombie et al. · Blood · 2019 · 31 citations

Medicine, Hematology, Pharmacology +10

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma

Jeremy S. Abramson, Elizabeth Bengston, Robert Redd et al. · Blood Advances · 2022 · 24 citations · Full text

Medicine, Oncology, Pharmacology +14

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Christine E. Ryan, Benjamin L. Lampson, Svitlana Tyekucheva et al. · Blood · 2022 · 23 citations

Medicine, Pharmacology, Pharmacotherapy +6